2019, Number 11
Characterization of immunohistochemical markers in surgical pathology of breast cancer in the north of Mexico
Pastén-Zapata AE, González-Habib R, Hernández-Salazar JA, Gómez-Torres PC
Full text
Language: Spanish
References: 13
Page: 734-739
PDF size: 247.28 Kb.
ABSTRACT
Objective: To describe the expression of immunohistochemical markers in breast cancer surgical pieces in women in a hospital in the north of Mexico.Materials and Methods: A descriptive and cross-sectional study; we inspect clinical records of women diagnosed with breast cancer who underwent surgery and immunohistochemical study at a private hospital in Monterrey, from 2013 to 2018. Inclusion criteria: Women of any age; with a diagnosis of breast cancer; surgically operated at the private hospital; with complete immunohistochemical markers. Exclusion criteria: men with breast cancer; incomplete immunohistochemical study; incomplete clinical history. The variables studied we included age, laterality, histological type, molecular subtype, histological grade, clinical stage, number of gestations and body mass index. In the statistical analysis, for the qualitative variables the χ2 test was used, to correlate quantitative variables the Spearman's Rho coefficient test was used and to see prediction and behavior of qualitative polytomous variables, multinominal logistic regression was performed.
Results: 136 files were analyzed; the average age at diagnosis of breast cancer was 54 years (± 25 and 87); In 12 patients the diagnosis was established before the age of 40. The most prevalent histological type was infiltrating ductal adenocarcinoma (94.9%), the most frequent molecular subtype was luminal A (66.9%). The molecular subtypes were correlated with stage IA, except HER-2 which did so with IIA.
Conclusions:The luminal tumor type A was the most frequent and with the best prognosis and luminal B had an intermediate survival. A high percentage of patients were positive for estrogen and progesterone receptors and lower for HER2/neu.
REFERENCES